A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model
Jérémy Brunet(Institut Pasteur), Nicolas Escriou(Institut Pasteur)
Cited by 1
Related Papers
Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome
|New England Journal of Medicine|2003|4.8k